TARA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Protara Therapeutics Inc (TARA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has some positive technical indicators and a favorable analyst rating, the lack of significant trading trends, poor financial performance, and absence of recent positive news or catalysts make it less compelling as an immediate investment opportunity.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.057, indicating a bullish trend. However, RSI is neutral at 50.086, and the stock is trading near its pivot point of 5.231. The next resistance is at 5.472, and support is at 4.99.
Analyst coverage from JPMorgan with an Overweight rating and a $27 price target, citing TARA-002 as a highly de-risked product with potential in bladder cancer and lymphatic malformations.
No significant news or trading trends from hedge funds, insiders, or Congress. The stock's financial performance remains weak with negative net income and declining EPS.
In Q4 2025, revenue remained at $0, net income improved by 35.54% YoY but is still negative at -$17.3M, and EPS dropped by -19.15% YoY to -0.38.
JPMorgan initiated coverage with an Overweight rating and a $27 price target, citing the potential of TARA-002 as a de-risked product.
